Literature DB >> 33704189

Resolution of Metastatic Subungal Eccrine Porocarcinoma Treated with Intralesional Interleukin-2.

Ashley Drohan1, Jennifer Melvin2, Joanne Murphy3, Carman Giacomantonio4, Lucy Helyer4.   

Abstract

Eccrine porocarcinoma is a rare aggressive cutaneous malignancy. Complete surgical excision is the standard of care, although there are high rates of local and distant recurrence. We present a unique case of locally recurrent and metastatic subungal porocarcinoma successfully treated with intralesional interleukin-2.

Entities:  

Keywords:  immunotherapy; interleukin-2; porocarcinoma

Year:  2020        PMID： 33704189      PMCID： PMC7900891          DOI： 10.3390/curroncol28010024

Source DB:  PubMed          Journal:  Curr Oncol        ISSN： 1198-0052            Impact factor:   3.677


  18 in total

1.  Pathologic complete response to intralesional interleukin-2 therapy associated with improved survival in melanoma patients with in-transit disease.

Authors:  Saima Hassan; Teresa M Petrella; Tong Zhang; Suzanne Kamel-Reid; Francesco Nordio; Andrea Baccarelli; Shachar Sade; Karen Naert; Ayman Al Habeeb; Danny Ghazarian; Frances C Wright
Journal:  Ann Surg Oncol       Date:  2014-11-01       Impact factor: 5.344

2.  Successful therapy of metastatic eccrine poroma using perilesional interferon alfa and interleukin 2.

Authors:  R Dummer; J C Becker; B Boser; A A Hartmann; G Burg
Journal:  Arch Dermatol       Date:  1992-08

3.  Intralesional Photodynamic Therapy for Eccrine Porocarcinoma.

Authors:  Daniele Torchia; Andrea Amorosi; Pietro Cappugi
Journal:  Dermatol Surg       Date:  2015-07       Impact factor: 3.398

4.  Metastatic eccrine porocarcinoma successfully treated with carboplatin and epirubicin chemotherapy.

Authors:  Keitaro Fukuda; Takeru Funakoshi; Masahiro Fukuyama; Risa Kakuta; Misato Sato; Yoshio Nakamura; Keiji Tanese; Yohei Masugi; Masayuki Amagai
Journal:  J Dermatol       Date:  2015-06-13       Impact factor: 4.005

5.  Successful treatment of porocarcinoma with maxacalcitol and imiquimod.

Authors:  Tomoya Nagasawa; Akiko Hirata; Shiro Niiyama; Yasunori Enomoto; Hidetsugu Fukuda
Journal:  Dermatol Ther       Date:  2019-02-07       Impact factor: 2.851

Review 6.  High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993.

Authors:  M B Atkins; M T Lotze; J P Dutcher; R I Fisher; G Weiss; K Margolin; J Abrams; M Sznol; D Parkinson; M Hawkins; C Paradise; L Kunkel; S A Rosenberg
Journal:  J Clin Oncol       Date:  1999-07       Impact factor: 44.544

7.  Eccrine porocarcinoma: epidemiologic and histopathologic characteristics.

Authors:  Lizbeth Riera-Leal; Elizabeth Guevara-Gutiérrez; Juan Gabriel Barrientos-García; Rodrigo Madrigal-Kasem; Gabriela Briseño-Rodríguez; Alberto Tlacuilo-Parra
Journal:  Int J Dermatol       Date:  2014-12-16       Impact factor: 2.736

8.  Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines.

Authors:  Franz O Smith; Stephanie G Downey; Jacob A Klapper; James C Yang; Richard M Sherry; Richard E Royal; Udai S Kammula; Marybeth S Hughes; Nicholas P Restifo; Catherine L Levy; Donald E White; Seth M Steinberg; Steven A Rosenberg
Journal:  Clin Cancer Res       Date:  2008-09-01       Impact factor: 12.531

Review 9.  Eccrine Porocarcinoma: New Insights and a Systematic Review of the Literature.

Authors:  Azadeh Nazemi; Shauna Higgins; Reyna Swift; Gino In; Kimberly Miller; Ashley Wysong
Journal:  Dermatol Surg       Date:  2018-10       Impact factor: 3.398

10.  Porocarcinoma: A systematic review of literature with a single case report.

Authors:  Abdulwahid M Salih; F H Kakamad; Rawand A Essa; Goran M Rauf; Masrur S A; Shvan H M; Rawezh Q S; Hunar A H; Dahat A H; Snur Othman
Journal:  Int J Surg Case Rep       Date:  2016-11-18
View more
  1 in total

1.  Cutaneous Breast Cancer Metastasis Is Effectively Treated With Intralesional Interleukin-2 and Imiquimod: A Case Report and Brief Literature Review.

Authors:  Ashley Drohan; Dejan Vidovic; Penelope Jane Barnes; Carman Anthony Giacomantonio; Lucy Kathryn Helyer
Journal:  Front Oncol       Date:  2022-05-30       Impact factor: 5.738
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.